IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.
Name:
IRIS study a phase II study of ...
Size:
512.7Kb
Format:
PDF
Description:
Open access full text article
Authors
Palmieri, CStein, R
Liu, X
Hudson, E
Nicholas, H
Sasano, H
Guestini, F
Holcombe, C
Barrett, S
Kenny, L
Reed, S
Lim, A
Hayward, L
Howell, Sacha J
Coombes, R
Affiliation
Department of Molecular and Clinical Cancer Medicine, University of Liverpool, LiverpoolIssue Date
2017-06-13
Metadata
Show full item recordAbstract
Irosustat is a first-generation, orally active, irreversible steroid sulfatase inhibitor. We performed a multicentre, open label phase II trial of the addition of Irosustat to a first-line aromatase inhibitor (AI) in patients with advanced BC to evaluate the safety of the combination and to test the hypothesis that the addition of Irosustat to AI may further suppress estradiol levels and result in clinical benefit.Citation
IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients. 2017 Breast Cancer Res TreatJournal
Breast Cancer Research and TreatmentDOI
10.1007/s10549-017-4328-zPubMed ID
28612226Type
ArticleLanguage
enISSN
1573-7217ae974a485f413a2113503eed53cd6c53
10.1007/s10549-017-4328-z
Scopus Count
Collections
Related articles
- IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer.
- Authors: Palmieri C, Szydlo R, Miller M, Barker L, Patel NH, Sasano H, Barwick T, Tam H, Hadjiminas D, Lee J, Shaaban A, Nicholas H, Coombes RC, Kenny LM
- Issue date: 2017 Nov
- A phase I dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer.
- Authors: Coombes RC, Cardoso F, Isambert N, Lesimple T, Soulié P, Peraire C, Fohanno V, Kornowski A, Ali T, Schmid P
- Issue date: 2013 Jul
- Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
- Authors: Gibson LJ, Dawson C, Lawrence DH, Bliss JM
- Issue date: 2007 Jan 24
- CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
- Authors: Gao JJ, Cheng J, Bloomquist E, Sanchez J, Wedam SB, Singh H, Amiri-Kordestani L, Ibrahim A, Sridhara R, Goldberg KB, Theoret MR, Kluetz PG, Blumenthal GM, Pazdur R, Beaver JA, Prowell TM
- Issue date: 2020 Feb
- A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer.
- Authors: Pautier P, Vergote I, Joly F, Melichar B, Kutarska E, Hall G, Lisyanskaya A, Reed N, Oaknin A, Ostapenko V, Zvirbule Z, Chetaille E, Geniaux A, Shoaib M, Green JA
- Issue date: 2017 Feb